Publications - Core B

Publications - Core B

Pharmacology of small- and intermediate-conductance calcium-activated potassium channels
Brown BM, Shim H, Christophersen P, Wulff H
Annu Rev Pharmacol Toxicol. 2020;60:219-240.

PMID 31337271

In vitro and in vivo metabolism of a potent inhibitor of soluble epoxide hydrolase, 1-(1-propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea
Wan D, Yang J., McReynolds CB, Barnych B, Wagner KM, Morisseau C,
Hwang SH, Sun J, Blöcher R, Hammock BD
Front. Pharmacol. 2019;10:464. PMC 6520522
PMCID: PMC6520522

1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea, a selective and potent dual inhibitor of soluble epoxide hydrolase and p38 kinase intervenes in Alzheimer's signaling in human nerve cells
Liang Z, Zhang B, Xu M, Morisseau C, Hwang SH, Hammock BD, Li QX
ACS Chem Neurosci. 2019;10:4018-4030. PMC 7028313

Antibodies and venom peptides: new modalities for ion channels
Wulff H, Christophersen P, Colussi P, Chandy KG, Yarov-Yarovoy V
Nat Rev Drug Discov. 2019 May;18(5):339-357. doi: 10.1038/s41573-019-0013-8.
PubMed PMID: 30728472; PMCID: PMC6499689

GABAA receptor subtype selectivity of the proconvulsant rodenticide TETS
Pressly B, Nguyen HM, Wulff H
Arch Toxicol. 2018 Feb;92(2):833-844. doi: 10.1007/s00204-017-2089-4. Epub 2017 Oct 16.
PubMed PMID: 29038840

Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121)
Brown BM, Shim H, Zhang M, Yarov-Yarovoy V, Wulff H
Mol Pharmacol. 2017 Oct;92(4):469-480. doi: 10.1124/mol.117.109421. Epub 2017 Jul 31.
PMID: 28760780

Rapid Throughput Analysis of GABAAReceptor Subtype Modulators and Blockers Using DiSBAC1(3) Membrane Potential Red Dye
Nik AM, Pressly B, Singh V, Antrobus S, Hulsizer S, Rogawski MA, Wulff H, Pessah IN
Mol Pharmacol. 2017 Jul;92(1):88-99. doi: 10.1124/mol.117.108563. Epub 2017 Apr 20.
PMID: 28428226

Recent developments in ion channel pharmacology
Wulff H, Christophersen P
Channels (Austin). 2015;9(6):335. doi: 10.1080/19336950.2015.1077650. Epub 2015 Nov 17. No abstract available.\
PMID: 26646476

Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1)
Christophersen P, Wulff H
Channels (Austin). 2015;9(6):336-43. doi: 10.1080/19336950.2015.1071748. Epub 2015 Jul 28. Review.
PMID: 26217968

Rapid throughput analysis demonstrates that chemicals with distinct seizurogenic mechanisms differentially alter Ca2+ dynamics in networks formed by hippocampal neurons in culture
Cao Z, Zou X, Cui Y, Hulsizer S, Lein PJ, Wulff H, Pessah IN
Mol Pharmacol. 2015 Apr;87(4):595-605. doi: 10.1124/mol.114.096701. Epub 2015 Jan 12.
PMID: 25583085

New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1
Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS, Köhler R, Wulff H
Mol Pharmacol. 2014 Sep;86(3):342-57. doi: 10.1124/mol.114.093286. Epub 2014 Jun 23.
PMID: 24958817

Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators
Jenkins DP, Yu W, Brown BM, Løjkner LD, Wulff H
Assay Drug Dev Technol. 2013 Nov-Dec;11(9-10):551-60. doi: 10.1089/adt.2013.543.
PMID: 24351043

The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases
Lam J, Coleman N, Garing AL, Wulff H
Expert Opin Ther Targets. 2013 Oct;17(10):1203-20. doi: 10.1517/14728222.2013.823161. Epub 2013 Jul 25. Review.
PMID: 23883298